Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effectiveness of Acular LS® and Lotemax® in the
prevention of inflammation in the eye after cataract surgery. Acular LS is made by Allergan,
Inc. It is a nonsteroidal anti-inflammatory drug (NSAID) and is approved by the Food and Drug
Administration (FDA) for use following cataract surgery. Lotemax is made by Bausch & Lomb. It
is a steroid and is also approved by the FDA for use following cataract surgery.